### INSTITUTIONAL PARTNERS

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATLANPOLE BIOOTHERAPIES</td>
<td>6</td>
</tr>
<tr>
<td>MEDICEN PARIS REGION</td>
<td>6</td>
</tr>
<tr>
<td>GLOBAL CARE</td>
<td>7</td>
</tr>
<tr>
<td>GENOPOLE</td>
<td>8</td>
</tr>
</tbody>
</table>

### COMPANIES

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFFILOGIC</td>
<td>10</td>
</tr>
<tr>
<td>ALIZE PHARMA</td>
<td>10</td>
</tr>
<tr>
<td>ALSACE INTERNATIONAL</td>
<td>11</td>
</tr>
<tr>
<td>AMYLGEN</td>
<td>11</td>
</tr>
<tr>
<td>ARIANA PHARMACEUTICALS</td>
<td>12</td>
</tr>
<tr>
<td>ATLANPOLE BIOOTHERAPIES</td>
<td>12</td>
</tr>
<tr>
<td>ATLANTIC BONE SCREEN</td>
<td>13</td>
</tr>
<tr>
<td>BIOALTERNATIVES</td>
<td>13</td>
</tr>
<tr>
<td>BIOMEDICAL TISSUES</td>
<td>14</td>
</tr>
<tr>
<td>CARLINA TECHNOLOGIES</td>
<td>14</td>
</tr>
<tr>
<td>CELLVAX SAS</td>
<td>15</td>
</tr>
<tr>
<td>CILOA SAS</td>
<td>15</td>
</tr>
<tr>
<td>CITOXLAB SAS</td>
<td>16</td>
</tr>
<tr>
<td>CYTUNE PHARMA</td>
<td>16</td>
</tr>
<tr>
<td>DRUGABILIS</td>
<td>17</td>
</tr>
<tr>
<td>EUKARYS</td>
<td>17</td>
</tr>
<tr>
<td>GENBIOTECH</td>
<td>18</td>
</tr>
<tr>
<td>GENOPOLE</td>
<td>18</td>
</tr>
<tr>
<td>ICM</td>
<td>19</td>
</tr>
<tr>
<td>ICTA</td>
<td>19</td>
</tr>
<tr>
<td>IN-CELL-ART</td>
<td>20</td>
</tr>
</tbody>
</table>
INSTITUTIONAL PARTNERS
MEDICEN PARIS REGION, excellence at the heart of Europe

MEDICEN PARIS REGION is your best gateway to access European biotechnologies and markets. Our mission is to maintain and reinforce the Paris Region as Europe’s leading industrial center for diagnostic innovation and health technologies.

3 R&D themes: 1) Translational medicine; 2) Biological tools for industrial use, biotherapeutic products; 3) Digital biology.

3 consolidated disease areas and 2 arising areas: 1) Cancer 2) Neurology 3) Infectiology 4) Cardiometabolism 5) Rare diseases.

Date of creation: 2005

CONTACT:
Francois CHEVILLARD
medicen@medicen.org
3-5, impasse Reille
75014 PARIS
Tel: +33 (0)1 79 68 10 86
www.medicen.org

ATLANPOLE BIOOTHERAPIES gives you access to extended skills, from biodiagnostics to biomedicine in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For pharmaceutical companies looking for high level partners devoted to healthcare and biotech, ATLANPOLE BIOOTHERAPIES is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France.

Date of creation: 2005

CONTACT:
Gregory BAUER
bauer@atlanpole.fr
95, route de Gachet
Château de la Chantrerie
44307 NANTES Cedex 3
Tel: +33 (0)2 40 25 27 20
www.atlanpolebiotherapies.fr

SECTOR: R&D Services/Biotechnologies
GLOBAL CARE is an outstanding consortium of 5 French expertise centers (honored by the Carnot institute label) research that covers 4 therapeutic fields of major interest in human health: oncology, ophthalmology, infectious diseases and neurology. Supported by our past experience in partnership research and in property management and by the fame of its members, GLOBAL CARE targets the international health market on emerging imaging technologies, innovative diagnostic tools and therapeutic advances. GLOBAL CARE offers behind a joint counter enlarged opportunities to our industrial and research partners worldwide. Bringing greater visibility to our R&D offers, GLOBAL CARE aims at mobilizing multi-disciplinary expertises in response to enterprise needs.

More detailed informations on the GLOBAL CARE consortium members below:

**Pasteur MI (Maladies Infectieuses)**
The “Pasteur Maladies Infectieuses” (“Pasteur Infectious Diseases”) Carnot institute includes five specialized departments of the “Institut Pasteur” (Virology, Microbiology, Parasitology & Mycology, Infection & Epidemiology, Cell Biology & Infection) that, together with four technological platforms, are dedicated to research on infectious diseases. It brings together basic and applied research activities involving numerous research partnerships with SMEs and large pharmaceutical and diagnostic companies.
The goal of research performed at the “Pasteur MI” Carnot institute is to understand basic mechanisms of host cells / pathogen interaction, to develop tools to diagnose known or emerging pathologies, and to perform the clinical validation of vaccines and therapeutic treatments. These works aim at providing an answer to today’s society expectations in public health problems, whether in developed countries (in particular AIDS, antibiotic resistance) or in developing countries (diseases of parasitic origin).

**“Seeing & Hearing Institute”**
Built in the heart of Paris, the “Seeing and Hearing” Carnot Institute is one of the most important research center in Europe on eye and audition diseases. Conceived as a place of gathering and exchanges, it brings together the three major actors of the fight against visual and auditive impairments: researchers, clinicians and industrial partners. This proximity enables the sharing of ideas, skills and platforms, the emergence of new questions and facilitates the delicate process of translating fundamental discoveries into new treatments. Our research and development activities are focused onto retinal neuroprotection, sensory readaptation, innovation in clinical investigation (imaging, diagnosis, surgery) and new solutions for the visually impaired people (smart-home, smart-city, accessible services).
The Institute’s goal is to discover, test and develop treatments and technological innovations of tomorrow in order to prevent or limit visual and auditive impairment and to improve the autonomy and the quality of life of patients.

**ICM** is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an rooted in Pitie-Salpetriere, the largest French Neurology Hospital. ICM aggregates more than 500 researchers, a clinical research facility, numerous technological platforms and a start-up incubator within the same building. Main research fields include Parkinson’s disease, Alzheimer, Huntington, ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials ongoing. It is also the national reference center for 13 rare neurological diseases.

**THE CURIE INSTITUTE** is a leading comprehensive Cancer Center in Paris, France, founded by Marie Curie in 1909. Our Technology Transfer&Licensing Department” is looking for industrial partners to develop patented innovation [120 families], to enter into preclinical R&D collaboration (drug discovery...) as well as into early-stage clinical collaborations.
GENOPOLE® is the leading French Science Park dedicated to life sciences.

Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientific instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to benefit from world-class hospitals, higher University education, biotech and pharma companies.

- 71 companies
- 21 academic research labs
- 2,148 staff

**Date of creation:** 1998
BIOTECHS COMPANIES
ALIZÉ PHARMA is a group of companies specialized in the development of innovative biopharmaceutical drugs for the treatment of metabolic diseases and rare diseases. **ALIZÉ PHARMA SAS** is dedicated to AZP-531, a peptide derived from unacylated ghrelin, currently in Phase I, to be developed in type 2 diabetes, the Prader Willi syndrome and some ischemia-related cardiovascular conditions. **ALIZÉ PHARMA II SAS**, is focused on ASPAREC®, a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, currently undergoing Phase I clinical development.

**CONTACT:**
Valérie WESLEY
vwesley@alz-pharma.com
15, chemin du Saquin
Espace européen - BAT G
69130 ECULLY
Tel: +33 (0)4 72 18 94 28
www.alz-pharma.com

**SECTOR:** Therapeutics

**THERAPEUTIC AREA:** • Endocrine&metabolic diseases • Cancer, Oncology
AMYLGEN has developed a unique and proprietary know-how on Alzheimer’s disease rodent models based on central injection of amyloid peptide fragments with validated predictive value. Other models for schizophrenia, depression, stroke are also available. AMYLGEN’s models and techniques allow fast-scale screening and pre-clinical validation for the pharmaceutical development of new drug candidates at a very early stage of development.

Date of creation: 1/10/2009
Nombre d’employés: 6
ARIANA® accurately identifies the best patient responder sub-groups in clinical trials, and optimizes biomarker/diagnostic signatures using its unique technology. ARIANA® applies its proprietary “rules-based” data analytical approach – KEM® - to clinical datasets to identify complex relations that all other approaches miss, thus enabling decision-makers to optimize all possible endpoints simultaneously. ARIANA®‘s world-class team of experienced, inter-disciplinary scientists includes PhD biologists, computer scientists, biostatisticians, bio-informatics specialists, chemists and clinical experts. ARIANA® was founded in 2003 as a spin-off from the Institut Pasteur, and has offices in Paris, France and Cambridge, Mass, USA.

Date of creation: 2003

ATLANPOLE BIOOTHERAPIES gives you access to extended skills, from biodiagnostics to biomedicine in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For pharmaceutical companies looking for high level partners devoted to healthcare and biotech, ATLANPOLE BIOOTHERAPIES® is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France.

Date of creation: 2005
ATLANTIC BONE SCREEN is a French Preclinical CRO providing biological evaluation services in the field of bone and joint diseases and in the field of bone tumors. We provide in vitro assays (bone and joint cells, tumor cells), in vivo assays (Experimental models in mice and rats: osteoporosis, osteoarthritis, rheumatoid arthritis, osteosarcoma, bone metastases from breast and prostate cancer), ex vivo analyses (histology, immunohistochemistry, imagery, ELISA assays).

ATLANTIC BONE SCREEN has an affiliated company, ATLANCHIMPHARMA provides custom-made chemical synthesis services.

Date of creation: October 2005
Nombre d’employés: 10

BIOALTERNATIVES is a private company [Contract Research Organization] specialized in Cellular and Molecular Pharmacology. BIOALTERNATIVES provides services to support the early stages of drug discovery and the claim substantiation of healthcare compounds using up-to-date in vitro solutions.

Date of creation: 1996
Nombre d’employés: 43
CARLINA TECHNOLOGIES is a biopharmaceutical company specialized in the development of micro- and nano-medicines. The company provides R&D formulation development services to the pharmaceutical, veterinary and biotechnology industries as well as it develops improved versions of first generation drugs for the treatment of cancer and diabetes using innovative encapsulation platforms.

Date of creation: 23 juillet 2010
CILOA SAS

SECTOR: • Therapeutics • R&D services/biotechnologies
THERAPEUTIC AREA: • Cardiovascular • Digestive system
• Diseases of the blood, immune disorders

CILOA offers custom production of fully native membrane proteins on exosomes, therapeutic mAbs against membrane proteins and collaboration for vaccine development. Ciloa has a full pipeline for mAb development with:
1. fully native membrane antigens (GPCRs, Kinase receptors, Ion channels, Viral Envelope proteins, etc.).
2. Hybridoma dev. with proprietary powerful immunization protocol.
3. Proprietary Human scFv Phage library focused on membrane Antigens.
4. ELISA screening & SPR characterization.

Date of creation: Mars 2011
Nombre d’employés: 8
CYTUNE develops CYP0150 that uniquely mimics the major MoA of IL-15 even in pathologic conditions. CYP0150 restores a potent but balanced immune response and is a unique opportunity within the successful family of anti-immunosuppressive agents such as anti-CTLA4 and anti-PD1. CYP0150 alone and in combination was shown to have promising efficacy in different animal tumor models and to be superior to IL-2. Moreover, CYTUNE develops a broad portfolio of potent immunocytokines, i.e., monoclonal antibody fused to CYP0150. These ICKs enable to manage the product Life Cycle Management for existing blockbusters and to increase the efficacy of existing or future antibodies.

Date of creation: 2007
High performance high yield cell-free messenger RNA production systems for research, cell therapies, human vaccines, cell reprogramming. The C3P3® mRNA Production System has three decisive competitive advantages: 1) increased mRNA yields; 2) fully mature mRNA with very high rate of native capping, and poly(A)tail, enhancing protein expression; 3) Easy-to-Use and Quick: One-step process instead of 3 or 4 to a produce completely capped, poly(A)-tailed mRNA. Other advantages: stability, immunogenicity, poly(A)-tails of equal or customized length, non-viral.

Date of creation: 210
Nombre d’employés: 3
GENOPOLE® is the leading French Science Park dedicated to life sciences. Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientific instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to benefit from world-class hospitals, higher University education, biotech and pharma companies.

- 71 companies
- 21 academic research labs
- 2 148 staff

Date of creation: 1998
ICTA

**SECTOR:** • Therapeutics • R&D services/biotechnologies • Diagnostic

**THERAPEUTIC AREA:** • Cardiovascular • Digestive system
• Diseases of the blood, immune disorders

**ICTA – INTERNATIONAL CLINICAL TRIALS ASSOCIATION**
11, rue du Bocage
21121 FONTAINE LES DIJON
Tel: +33 (0)3 80 53 40 00
www.icta.fr

**CONTACT:**
Olivier HUMBEY
olivier.humbey@icta.fr

**International Office**
ICTA GmbH - Lebacher Strasse 4 - D-66113 Saarbrücken

**Date of creation:** 01/05/1984
**Nombre d’employés:** 350

ICTA is an international privately-owned CRO with 30 years of experience in clinical R&D, pharmaco-epidemiology and expanded access programs for APIs, cell therapies, diagnostics and medical devices. ICTA’s international operations in Europe and the USA provide full clinical research or “a la carte” services in traditional and adaptive clinical trials from Early Phase to Late Phase across a broad range of therapeutic areas...

---

ICM

**SECTOR:** R&D services/biotechnologies

**THERAPEUTIC AREA:** • Disease of nervous system • Mental & behavioural disorders • Cancer, oncology

**BRAIN & SPINE INSTITUTE [ICM]**
Hôpital Pitié Salpêtrière
47, boulevard de l’Hôpital
75013 PARIS
Tel: +33 (0)1 57 27 40 00
http://research.icm-institute.org/

**CONTACT:**
Alexis GENIN
Directeur des Applications de la Recherche
alexis.genin@icm-insitute.org

**ICM** is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an rooted in Pitie-Salpetriere, the largest French Neurology Hospital. ICM aggregates more than 500 researchers, a clinical research facility, numerous technological platforms and a start-up incubator within the same building. Main research fields include Parkinson’s disease, Alzheimer, Huntington, ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials ongoing. It is also the national reference center for 13 rare neurological diseases.

**Date of creation:** 2010
**Nombre d’employés:** 600
IRIS PHARMA

SECTOR: • R&D services/biotechnologies
THERAPEUTIC AREA: • Disease of ear or eye

CONTACT: Pierre-Paul ELENA
info@iris-pharma.com
Allée Hector Pintus
06610 LA GAUDE
Tel: +33 (0)9 35 94 59 59
www.iris-pharma.com

A leading contract research organization (CRO) dedicated to ophthalmology, IRIS PHARMA helps clients around the world navigate every stage of the drug and device development process – including in vivo screening, proof of concept, ocular efficacy, GLP preclinical studies, bioanalysis, clinical trials, and marketing surveys. IRIS PHARMA has partnered with clients to bring more than 40 ocular drugs and medical devices to market in the past 24 years, in addition to offering consulting services to help clients determine the best indication for molecules and products in development. This CRO has expertise in all ophthalmic indications, and supports clients ranging from small start-ups to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.

Date of creation: 1989
Nombre d'employés: 60

ICA was founded in 2005 by a research team including a Nobel Prize laureate. ICA is specialized in nanocarriers for macromolecule delivery and it has collaborations with DARPA (US Ministry of Defense), Sanofi Pasteur, Merial and more. In 2012, Deloitte awarded ICA as one of the fastest growing biopharmaceutical firms between 07 and 11 in France. Currently, ICA has 4 core activities based on the delivery system: Vaccine, Gene Therapy, Antibody Discovery and iPSc,

Date of creation: 2005

IN-CELL-ART

SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologies
THERAPEUTIC AREA: • Infectious and parasitic diseases • Cancer, oncology

CONTACT: Sohei FUKUYAMA
MBA Business Development & Alliance Management
sohei.fukuyama@incellart.com
21, rue de la Noue Bras de Fer
44200 NANTES
Tel: +33 (0)2 40 71 67 17
www.incellart.com

IN-CELL-ART was founded in 2005 by a research team including a Nobel Prize laureate. ICA is specialized in nanocarriers for macromolecule delivery and it has collaborations with DARPA (US Ministry of Defense), Sanofi Pastuer, Merial and more. In 2012, Deloitte awarded ICA as one of the fastest growing biopharmaceutical firms between 07 and 11 in France. Currently, ICA has 4 core activities based on the delivery system: Vaccine, Gene Therapy, Antibody Discovery and iPSc,
LEADS TO DEVELOPMENT (L2D) specializes in the early-stage development of therapeutic products. We offer consultancy, regulatory and operational management services to our clients in order to help them bridge the gap between therapeutic lead identification and clinical development. Our clients benefit from our development expertise without having to build additional internal headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical proof of concept. We offer a personal service carefully tailored to our customers’ needs that maintains the transparency, flexibility and availability associated with an internal team.

Date of creation: 2009
Nombre d’employés: 5

LEADSTODEVELOPMENT
Non-clinical development expertise

CONTACT:
J. KEARSEY
jkearsey@leadstodevelopment.com

LEADSTODEVELOPMENT
166, boulevard du Montparnasse
75014 PARIS
www.leadstodevelopment.com

SECTOR: R&D services/biotechnologies

KEOSYS Medical Imaging is a global company specialized in IT applied to Medical Imaging within clinical research and medical diagnosis. KEOSYS offers full medical imaging services for phase II–III–IV drug and device medical imaging clinical trials whatever the imaging modalities and the therapeutic areas. KEOSYS’ expertise relies on its deep knowledge of the medical imaging requirements in clinical study projects and on its expert medical team (radiologists, nuclear medicine physicians, gastroenterologists, cardiologists, neurologists, rheumatologists, dermatologists...).

Date of creation: 2001

KEOSYS
1, Impasse Augustin Fresnel
44815 SAINT-HERBLAIN
Tel: +33 (0)2 40 92 26 13
www.keosys.com

CONTACT:
Lydia BEHLOUL
lbe@keosys.com

International Office
Philadelphia (U.S.A)

SECTOR: • Diagnostic • R&D services/biotechnologies
• Other: [developpement agency, association, institution, cluster]

Medical Imaging Services for clinical Trials

THERAPEUTIC AREA: • Cardiovascular • Digestive system
• Diseases of the blood, immune disorders

L2D SERVICES SARL

CONTACT:
J. KEARSEY
jkearsey@leadstodevelopment.com

L2D SERVICES SARL
166, boulevard du Montparnasse
75014 PARIS
www.leadstodevelopment.com

SECTOR: R&D services/biotechnologies
METABOLYS SAS

SECTOR: • Therapeutics • R&D services/biotechnologies
THERAPEUTIC AREA: • Disease of nervous system
• Endocrine & metabolic diseases • Cancer, oncology

CONTACT: Gabriel BAVEREL
baverel@metabolys.com
Laennec Faculty of Medicine
7-11, rue G. Paradin
69008 LYON
Mob.: +33 (0)6 84 85 57 75
www.metabolys.com

METABOLYS has a drug discovery line in the diabetes field. Six antidiabetic candidates are protected by 4 patents; one of them is being developed and will be out-licensed.
METABOLYS has also a service activity consisting of predicting the safety and efficacy of drug candidates using a metabolic flux analysis approach.

Date of creation: 20/11/2008
Nombre d’employés: 6

MEDINCELL

SECTOR: Therapeutics
THERAPEUTIC AREA: • Cardiovascular • Digestive system
• Diseases of the blood, immune disorders

Parc Clément Ader
1, avenue Charles Cros
34830 JACOU
Tel: +33 (0)4 67 41 99 74
www.medincell.com

MEDINCELL’s controlled-release delivery platform offers wide-ranging durations—from several days up to one year—for many small molecules and biologics, and requires no API modification. Current commercial partnerships aim to address delivery hurdles across arthritis, oncology, contraception, diabetes, and our low-cost manufacturing enables partners to target fast-growing emerging markets.

CONTACT: Sebastien ENAULT
sebastien.enault@medincell.eu
International Office
MedinCell Corporation
10451 Roselle St, Suite 200
San Diego CA 92121

Date of creation: 2002
MYELOMAX is a French CRO specialized in preclinical evaluation services in the field of multiple myeloma. Our mission is to assist our clients in the evaluation of drug efficacy, mechanism of action, combination with approved drugs, identification of biomarkers using our large and unique collection of Human Multiple Myeloma Cell Lines covering the molecular and functional diversity of Multiple Myeloma.

CONTACT: contact@myelomax.com

IRS_UN
8, quai Moncousu
44007 NANTES
Tel: +33 (0)2 28 08 00 40
www.myelomax.com

METABRAIN is a diabetes research center (Paris area). Its 30 collaborators operate integrated and disease-oriented medicinal chemistry, molecular, cellular and animal pharmacology, gather long-term industrial experience in discovery and drug development. Since 2009, METABRAIN is conducting research partnerships with main French Biotechs and Pharmas. It develops drugs and nutraceuticals and associated biomarkers that address several interconnected chronic diseases such as diabetes, obesity, muscle dysfunction and memory troubles, for the elder population which requires alternatives to existing therapies.

CONTACT: Valerie AUTIER
v.autier@metabrainresearch.com

4, avenue du pdt f. Mitterrand
91380 CHILLY MAZARIN
Tel: +33 (0)1 69 19 41 50
www.metabrainresearch.com

SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologies
THERAPEUTIC AREA: • Cardiovascular • Disease of nervous system
• Endocrine & metabolic diseases

Date of creation: 10/03/2009
Nombre d’employés: 30

SECTOR: R&D services/biotechnologies
THERAPEUTIC AREA: • Cancer, oncology

CONTACT: contact@myelomax.com

IRS_UN
8, quai Moncousu
44007 NANTES
Tel: +33 (0)2 28 08 00 40
www.myelomax.com
OXELTIS

SECTOR: R&D services/biotechnologies
THERAPEUTIC AREA: • Infectious and parasitic diseases • Cancer, oncology

Cap Gamma
1682, rue de la Valsière
C.S. 27384
34189 MONTPELLIER Cedex 4
Tel: +33 (0)4 99 23 50 36
www.oxeltis.com

CONTACT:
Jean-Marc ALLAIRE
contact@oxeltis.com

OXELTIS is a medicinal chemistry service company delivering integrated solutions for managing and executing medicinal and fine organic chemistry projects in the field of NCE discovery and optimization. **OXELTIS** is particularly active in the anti-infective and oncology fields. **OXELTIS** team expertise and background is related to medchem research for the past 10 years. Its expertise in organic chemistry is in heterocycles, macrocycles, sugars, nucleos(t)ides and phosphorus chemistry. **OXELTIS** is located in Montpellier-France and was founded in 2010 by former management and research team from Idenix Pharmaceuticals.

Date of creation: September 2010

OTR3

SECTOR: Therapeutics
THERAPEUTIC AREA: • Cancer, oncology • Skin & subcutaneous tissue

4, rue Française
75001 PARIS
Tel: +33 (0)1 83 62 78 83
www.otr3.com

CONTACT:
Denis BARRITAULT
denis.barritault@otr3.com

OTR3 is developing products in regenerative medicine from innovative proprietary molecules: the RGTA. RGTA are biodegradable polysaccharides engineered to restore the cellular microenvironment after lesion and favor tissue regeneration without external input of stem cells. Two products are on the market: CACIPLIQ20 and CACICOL20 to treat skin and corneal ulcers. Two developments are in clinical trials to treat mucositis and radiation dermatitis in cancer patients. Marketing authorization is expected within 1 year. **OTR3** is looking for licensees and development partners.

Date of creation: July 2000
Nombre d’employés: 13
PELVIPHARM is a CRO delivering preclinical research services across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC...), sexual (ED, PE, FSD...) and cardiovascular medicine (Hypertension, Atherosclerosis, Metabolic Syndrome, Diabetes, Myocardial Infarction...). PELVIPHARM provides customized outsourcing services to clients according to their outsourcing needs, using both in vivo experimental models and in vitro animal and human tissue-based specific research services based on the most recent exploration methods.

Date of creation: 1999
Nombre d’employés: 14 FTE

CONTACT:
Delphine BEHR-ROUSSEL
d.behr.roussel@pelvipharm.com

Orsay Parc
86, rue de Paris
91400 ORSAY
Tel: +33 (0) 1 70 42 93 39
www.pelvipharm.com

PORsOLT is a long-established preclinical CRO with an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric & neurological diseases, acute & chronic pain, inflammation, cardiovascular diseases, and metabolic disorders. PORsOLT also offers services for safety evaluation of drug candidates from screening to pre-Phase 1 regulatory studies (ICH S7), in full GLP compliance. PORsOLT’s safety program includes full assessment of arrhythmogenic risk and abuse/dependence liability.

Date of creation: 1984

CONTACT:
Sébastien BRECHE
sbreche@porsolt.com

Z.A. de Glatigné
53940 LE GENEST SAINT ISLE
Tel: +33 (0) 2 43 69 36 07
www.porsolt.com
PRESTWICK CHEMICAL SAS

SECTOR: • Therapeutics • R&D services/biotechnologies
THERAPEUTIC AREA: • Cardiovascular • Digestive system
• Disease of nervous system

220, boulevard Gonthier d’Andernach
STRASBOURG-ILLKIRCH
Tel: +33 (0)3 69 20 16 00
www.prestwickchemical.com

CONTACT:
Paul BIKARD
paul.bikard@prestwickchemical.fr

PRESTWICK CHEMICAL is a drug discovery company that successfully identifies hits for the project’s target and optimizes the hits into clinical candidates. With our premium partners, we have developed the capacity to integrate the whole drug research: Hit identification using smart screening libraries and/or large scale pharmacophore based virtual screening, hit validation, hit to lead expansion, lead optimization and profiling and have unprecedented success towards development.

Date of creation: 1999

POXEL SA

SECTOR: • Therapeutics
THERAPEUTIC AREA: • Endocrine&metabolic diseases

200, avenue Jean Jaurès
69007 LYON
Tel: +33 (0)4 37 37 20 10
www.poxel.com

CONTACT:
Pascale MALGOUYRES
pascale.malgouyres@poxelphama.com

POXEL is a biopharmaceutical company developing innovative first-in-class drugs with a primary focus on Type 2 diabetes. The company develops novel treatments before partnering with pharmaceutical companies. POXEL operates independently as a lean organization with strong in-house drug development and business expertise. Its R&D pipeline consists in innovative programs with new mechanism of action, agents profiled for their activity on glucose metabolism and cardiovascular risk factors, all with an improved safety profile compared to current available therapies.

Date of creation: 2009
Nombre d’employés: 13
**PX’THERAPEUTICS**

**SECTOR:** R&D services/biotechnologies  
**THERAPEUTIC AREA:**  
- Cardiovascular  
- Digestive system  
- Diseases of the blood, immune disorders

**CONTACT:**  
Claire UNTEREINER  
claireuntereiner@px-therapeutics.com  
Minatec BHT52A  
7, parvis Louis Néel  
38040 GRENOBLE  
Tel: +33 (0)4 38 02 36 50  
www.px-therapeutics.com

**PUP PHARMA**’s unique experimental services tailored to our customer’s specific perinatal and paediatric applications, allowed preclinical efficacy and safety drug evaluation in the context of pathological/physiological conditions from prematurity to childhood. Our pharmacological services allow either complying with the mandatory Pediatric Investigation Plan or identifying new indications for yours products in the field of Central Nervous System, Pulmonary or Inflammatory Systems.

**Date of creation:** aout 2010
**SKULDTECH**

**SECTOR:** • Diagnostic • R&D services/biotechnologies  
**THERAPEUTIC AREA:** • Disease of nervous system  
• Infectious and parasitic diseases • Cancer, oncology

1682, rue de la Valsière  
C.S. 77394  
34184 MONTPELLIER  
Tel: +33 (0)4 67 41 97 48  
www.skuldtech.com

**CONTACT:**  
Didier RITTER  
info@skuldtech.com

**SKULDTECH** aims to discover and validate new genomic and pharmacogenomic biomarkers for diagnostics and therapeutic purposes. Its approach is based on ”Digital Gene Expression” method, New Generation Sequencing (NGS) technologies associated with its proprietary bioinformatics and biostatistics tools. This expertise enables the Company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new therapeutics especially in cancer, rare diseases and infectious diseases.

**Date of creation:** 14/06/1999

---

**QUINTEN**

**THERAPEUTIC AREA:** • Cardiovascular • Digestive system  
• Diseases of the blood, immune disorders

11, rue Galvani  
75017 PARIS  
Tel: +33(0)1 45 74 33 05  
www.quinten.com

**CONTACT:**  
Alexandre TEMPLIER  
a.templier@quinten-france.com

**QUINTEN** is a strategy and operations consulting firm specialized in leveraging biomedical data for pharmaceutical, biotechnology and cosmetics companies. **QUINTEN**’s knowhow complements traditional modeling and data-mining techniques, since it enables to identify, characterize and enhance the value of sub-groups corresponding to best and worst practice in terms of patients’ response or resistance to a treatment, and occurrence of undesirable side-effects.

**Date of creation:** 4/11/2008  
**Nombre d’employés:** 15
TEXCELL is a world-renowned company that provides Biosafety and immunology services in full compliance with GLP and GMP standards. Thanks to our in-depth experience of providing viral safety testing and virus validation studies, we have provided support to a large number of products licensed by the FDA, the EMA and the MHW. TEXCELL is also your central lab for pre-clinical and clinical trials. We offer a dedicated technology platform in immunology. Based in France near Paris (Evry), TEXCELL has also a subsidiary in USA, with facilities in Middletown, MD., and soon in Frederick, specialized in no GMP Cell culture and GLP compliant viral clearance testing services.

Date of creation: 1987

CONTACT:
Bernard PLICHON
info@texcell.com
Bât. Genavenir 5
1, rue Pierre Fontaine
91058 EVRY Cedex
Tel: +33 (0)1 60 91 33 10
www.texcell.com

SYNCROSOME is focused on In Vivo Efficacy Studies dedicated to Discovery and Preclinical stage with more than 25 Animal Models, to provide you the right data to make the right decision. We offer our services and our expertise in the development of drugs in: GASTROENTEROLOGY, CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR, RESPIRATORY, INFLAMMATION. We perform also Pharmacokinetics studies (multi-species). Concerning PK studies, we pay a special attention to CNS-PK to evaluate the in vivo BBB passage of your compounds.

Date of creation: 2000
Nombre d’employés: 14

CONTACT:
Arnaud PEYRONNIER
dvpt@syncrosome.com
Case Postale 908
Luminy biotech entreprises
163, avenue de Luminy
13288 MARSEILLE
Tel: +33 (0)4 95 05 31 80
www.syncrosome.com

SECTOR: R&D services/biotechnologies
THERAPEUTIC AREA: • Cardiovascular • Digestive system • Disease of nervous system
VFP THERAPIES is a young French company who has devised an innovative therapeutic approach aimed at treating brain diseases such as Alzheimer’s Disease by means of highly selective bioprecursor drugs. Such prodrugs do not deploy activity before they crossed the blood-brain-barrier, and hence do not induce significant side effects. Besides, one can target receptor sites in the brain in a more selective way. The required amount of active principle as well as its toxicity can thereby be decreased. The core business of VFP THERAPIES is the development of proprietary drugs at the same time as joined development work on behalf of pharmaceutical and biotechnology companies.

Date of creation: août 2012
Nombre d’employés: 6
BIO EUROPE 2013 CONVENTION
The French participation is organized by UBIFRANCE

HEAD OFFICE IN PARIS
77, boulevard Saint-Jacques
75014 PARIS - FRANCE
Tel: +33 (0)1 40 73 33 88
Fax: +33 (0)1 40 73 30 39
Jennifer OLSZOWY
jennifer.olszowy@ubifrance.fr

CONTACT IN AUSTRIA
UBIFRANCE Vienna
Reisnerstrasse 50/10
1030 VIENNE - AUTRICHE
Tel: +43 (0)1 712 63 57 64
Mascha PAULIN
mascha.paulin@ubifrance.fr

WEBSITE
www.ubifrance.com